Watson Responds To FDA-483 For Corona, Calif. Facility
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA identified GMP issues related to laboratory test messages and documentation procedures, the company says. Watson met with the agency to discuss ongoing and future corrective actions.